Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers

NEXT STORY
10x Genomics Reports Third Quarter 2019 Financial Results and Provides 2019 Revenue Guidance
PREV STORY
AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Medicenna Receives Award for Excellence in Clinical Trials in Connection with an Upcoming Presentation at the 26th Annual Meeting of the Society for Neuro-Oncology

author_avatar
NASDAQ Market News

Radius Health to Present at the 35th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven ...

author_avatar
NASDAQ Market News

Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

- Bone, Reproductive, and Urologic Drugs Advisory Committee Votes Unanimously in Favor of Unified ...

author_avatar
NASDAQ Market News